NCT05307328 - SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

August 1, 2025

Study Completion Date

August 1, 2025

Conditions

Cushing's Syndrome ICushing Disease Due to Increased ACTH SecretionCortisol ExcessCortisol; HypersecretionCortisol OverproductionEctopic ACTH Secretion

Interventions

DRUG

SPI-62

11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor

DRUG

Placebo

Inactive tablets identical to SPI-62 tablets

Trial Locations (12)

1431

Clinical Center of Endocrinology and Gerontology, University Hospital of Endocrinology, Medical University Sofia (USHATE), Sofia

Medical University of Sofia, Sofia

4002

Medical University of Plovdiv, Plovdiv

10065

Memorial Sloan-Kettering Cancer Center, New York

15213

University of Pittsburgh Medical Center, Pittsburgh

33907

Southwest General Healthcare Center, Fort Myers

55905

Mayo Clinic Cancer Center (MCCC) - Rochester, Rochester

63110

Washington University School of Medicine - Center for Advanced Medicine (CAM), St Louis

85013

St. Joseph's Hospital and Medical Center - Barrow Neurological Institute (BNI) - Pituitary Center, Phoenix

89052

Comprehensive and Interventional Pain Management Llp, Henderson

97239

Oregon Health & Science University (OHSU) - Northwest Pituitary Center, Portland

050474

Carol Davila University of Medicine and Pharmacy, Bucharest